Drug Trial Radar · NCT00254956
Effects Of Ciclesonide And Beclomethasone On Lens Opacification In Adult Subjects With Moderate To Severe Persistent Asthma
Last checked: Nov 19, 2026Latest source record: Apr 8, 2009 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,568
Actual
Start
Jan 2004
Primary completion
Jun 2005
Study completion Jun 2005
Sponsor
- Lead sponsor
- SanofiSanofi (SNY)
- Sponsor type
- Industry
- Collaborators
- Takeda
- First posted
- Nov 17, 2005
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective is to demonstrate the non-inferiority of ciclesonide compared to beclomethasone-HFA in the occurrence of Class 1 lens event for nuclear (NO), cortical (C), or posterior subcapsular (P) lens opacification within 12 months. Secondary objectives are to compare ciclesonide and beclomethasone with respect to class II and class III best corrected visual acuity and intraocular pressure from baseline to 12 months.
Conditions
- Respiratory Tract Diseases
- Respiratory Hypersensitivity
- Asthma
Interventions
ciclesonide (XRP1526)Drug
Primary outcomes
What the sponsor says the trial is designed to measure.
- The primary endpoint is the occurrence of a Class I lens event for nuclear (NO), cortical (C), or posterior subcapsular (P) lens opacification within 12 months.
- A Class I lens event is defined as any of the following events in either eye:
- - 1.Increase from baseline in LOCS III grade of ≥ 0.5 (NO), ≥ 0.8 (C), or ≥ 0.5 (P)
- - 2.Cataract surgery
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Sanofi-Aventis
Chilly-Mazarin, France
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.